Initial combination therapy with metformin plus Colesevelam in drug-naïve hispanic patients with early type 2 diabetes

Postgraduate Medicine

Volumn 124, Issue 4, 2012, Pages 7-13

  Rosenstock, Julio ^a   Hernandez Triana, Eric ^b   Handelsman, Yehuda ^c   Misir, Soamnauth ^d   Jones, Michael R ^d   Nagendran, Sukumar ^d  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b UNIVERSIDAD DEL ROSARIO   (Colombia)

^c Metabolic Institute of America   (United States)

^d DAIICHI SANKYO INC   (United States)

Author keywords

Bile acid sequestrant; Colesevelam; Hispanic; Metformin; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; COLESEVELAM; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TRIACYLGLYCEROL; ALLYLAMINE; ANTIDIABETIC AGENT; CHOLESTEROL; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; GASTRITIS; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; ETHNOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS; MALE; METFORMIN; TREATMENT OUTCOME;

EID: 84871672045     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.07.2560     Document Type: Article

References (24)

1. International Diabetes Federation. IDF Diabetes Atlas; Central and South America. 2009. http://www.idf.org/diabetesatlas/south-and-central-america. Accessed August 18, 2011.
2. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009;32(2):287-294.
3. Maskarinec G, Grandinetti A, Matsuura G, et al. Diabetes prevalence and body mass index differ by ethnicity: the Multiethnic Cohort. Ethn Dis. 2009;19(1):49-55.
4. US Department of Health and Human Services, Office of Minority Health. Diabetes and Hispanic Americans. 2010. http://minorityhealth.hhs.gov/templates/content.aspx?lvl=3&lvlID=5&ID=3324. Accessed July 28, 2011.
5. Willey JZ, Rodriguez CJ, Carlino RF, et al. Race-ethnic differences in the association between lipid profile components and risk of myocardial infarction: The Northern Manhattan Study. Am Heart J. 2011;161(5):886-892.
6. Caballero AE. Understanding the Hispanic/Latino patient. Am J Med. 2011;124(10 suppl):S10-S15.
7. Rosenstock J, Fonseca VA, Garvey WT, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010;16(4): 629-640.
8. Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm. 2006;12(6):466-471.
9. Kennedy AG, MacLean CD, Littenberg B, Ades PA, Pinckney RG. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care. 2005;28(5):1029-1034.
10. Jones MR, Mudaliar S, Hernandez-Triana E, et al. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Curr Med Res Opin. 2009;25(9):2239-2249.
11. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975-1983.
12. Bays HE. Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies. Endocr Pract. 2011;17(6):933-938.
13. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
14. Handelsman Y, Mechanick JI, Blonde L, et al; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(suppl 2):1-53.
15. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with mac-rovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
16. Cholesterol Treatment Trialists' (CCT) Collaborators; Kearney PM, Blackwell PM, Collins R. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet. 2008;371(9607):117-125.
17. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
19. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators. Primary prevention of cardiovascular disease with ator-vastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.
20. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012.
21. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care. 2006;29(3):504-509.
22. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541-549.
23. Rains SG, Wilson GA, Richmond W, Elkeles RS. The effect of gliben-clamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med. 1988;5(7):653-658.
24. Rains SG, Wilson GA, Richmond W, Elkeles RS. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. J R Soc Med. 1989;82(2):93-94.